Clinical Trial Update: JS001 Combined With Regorafenib in Patients With Advanced Colorectal Cancer [Phase 1, Phase 2]

View source ↗

Summary

A clinical trial update on JS001 combined with regorafenib in advanced colorectal cancer, covering Phase 1 and Phase 2 stages.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• JS001 (PD-1 inhibitor)
• Regorafenib (regorafenib)

Snippet

Sponsor: Sun Yat-sen University | Conditions: Colorectal Cancer | Phase 1, Phase 2 | Status: UNKNOWN